Covid-19

#AMR #CDMO #Covid-19 #Immunology / Virology & Vaccines #RNA

Vaccine nationalism, AMR & CDMO expansion ahead for 2021

The new CPhI report looks ahead to a post-pandemic 2021 with pharma manufacturing capacity and payment structures shifting as new sourcing strategies emerge. It explores the potential implications in 2021 of impending vaccine approvals, a new administration in the White House and a return to dual supply chain strategies. The report… Read More

#Business & Investment #Covid-19 #Editor's Choice #Market Reports #News

#Covid-19 #Immunology / Virology & Vaccines

Less than half of people currently willing to get a COVID-19 vaccine, international survey suggests

A new report on the public’s attitudes towards coronavirus vaccines has revealed that around half of those surveyed (51%) may be willing to get vaccinated next year. Findings from a survey of 13,500 people across 15 countries* in November suggest that fewer would be willing if a vaccine were to… Read More

#Covid-19 #Editor's Choice #News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

UC Davis Health joins Novavax in testing new COVID-19 vaccine

Despite the encouraging news of potentially successful COVID-19 vaccine trials, there is not yet an FDA-approved vaccine available. Research into other effective coronavirus vaccines continues, including at UC Davis Health. The health system is expected to launch a stage III clinical trial with the National Institutes of Health (NIH) and… Read More

#Covid-19 #News

#Clinical trials #Covid-19 #Vaccines

The ethics of human challenge trials

Rutgers Research Professor, Daniel Hausman, examines the ethical questions around human challenge trials for COVID-19 vaccines The first human challenge trial to test COVID-19 treatments and vaccines is set to begin in January in the United Kingdom. These trials, in which healthy volunteers are infected with the virus after being… Read More

#Covid-19 #Editor's Choice #News #Opinion

#Covid-19 #Immunology / Virology & Vaccines

Oxford vaccine: latest efficacy results released

University of Oxford and AstraZeneca researchers have released a pooled analysis of Phase III trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%. The new study published in the Lancet is the first peer-reviewed publication of Phase III data from studies of… Read More

#Covid-19 #News #Trending News

#Biologics / Biotechnology #Covid-19 #Immunology / Virology & Vaccines #Pharmaceutical

Seppic boosts presence in the human vaccine adjuvant market

Seppic’s Sepivac SWETM vaccine adjuvant for human use can contribute to the development of vaccine solutions to fight seasonal and pandemic influenza, as well as COVID-19. Together with various international partners, Seppic is participating in the global research effort to develop a vaccine solution against COVID-19. These programs are in… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

Moderna vaccine: helps antibodies last for three months

In a letter published in the New England Journal of Medicine, Moderna has reported that participants in the Phase I study its mRNA-1273 COVID-19 vaccine candidate, retained high levels of neutralising antibodies for 119 days following first vaccination (90 days following second vaccination). The study was led by the National Institute… Read More

#Covid-19 #News #Trending News

#Biotechnology #Cell therapy #Covid-19 #Gene therapy #Immunology / Virology & Vaccines #Pharmaceutical

Investment banking head offers market outlook for 2021

The Jefferies Healthcare Temperature Check report is now in its third edition and published to coincide with the 11th annual Global Healthcare Conference which was held virtually. Over 500 responses from senior leaders in the sector responded for this year’s report, giving views on both the current state of the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #Market Reports #News #Opinion #Trends & Analysis

#Covid-19 #Therapeutics

How SARS-CoV-2 hijacks and damages lung cells offers insight for therapeutic targets

In a collaboration  involving the National Emerging Infectious Disease Laboratories (NEIDL), the Center for Regenerative Medicine (CReM), and the Center for Network Systems Biology (CNSB), scientists have reported the first map of the molecular responses of human lung cells to infection by SARS-CoV-2. By combining bioengineered human alveolar cells with… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

Pfizer vaccine approval: biotech innovation brings positivity for UK private sector

This week has provided hope and optimism that the end of the pandemic is finally in sight, with the UK becoming the first country in the world to approve the Pfizer/BioNTech coronavirus vaccine for widespread use. With almost half of Britain now in Tier 3 and many small businesses facing… Read More

#Business & Investment #Covid-19 #Editor's Choice #Exclusive Content #News #Trending News

#AI / data analytics / healthtech / informatics #Covid-19

Watch now: COVID Moonshot – Data Coordination Strategy

The COVID Moonshot is a global consortium that aims to rapidly develop antivirals for COVID-19. Dr. Lizbe Koekemoer of Oxford University describes how the project team leverages the CDD Vault informatics platform to effectively store, manage, and share data among multiple international partners.    … Read More

#Covid-19 #Videos

#Covid-19 #Immunology / Virology & Vaccines #Marketing approval authorisation

Pfizer / BioNTech vaccine approved and available for use in the UK next week

The Pfizer/BioNTech COVID-19 vaccine has been authorised for emergency use by the Medicines and Healthcare Products Regulatory Authority (MHRA). Pfizer and BioNTech recently announced final efficacy analysis in their Phase III study for their mRNA-based COVID-19 vaccine candidate BNT162b2, which showed an efficacy rate of 95% in participants without prior… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Novavax updates on COVID-19 vaccine development

Novavax a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, has released an update on its COVID-19 vaccine. NVX‑CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with the company’s proprietary Matrix‑M. “Novavax is in a… Read More

#Covid-19 #Editor's Choice #News